Technology | June 27, 2014

Mobius Medical Systems Receives FDA Clearance for Mobius3D Software

Mobius 3D Mobius Medical Systems LP FDA Clearance

June 27, 2014 — Mobius Medical Systems LP’s Mobius3D software has received U.S. market clearance as a Class II medical device from the U.S. Food and Drug Administration (FDA).

Mobius3D software is used for quality assurance (QA) and treatment plan verification in radiation therapy. It calculates 3-D radiation dose directly on a patient's computed tomography (CT) scan or a phantom. The calculation is based on treatment plans initially calculated by a planning system. The MobiusFX module allows users to perform calculations based on linac delivery log data.

Mobius3D is the first software to verify patient plans in 3-D using an independently developed TPS quality algorithm. Mobius3D works with all major linear accelerators, offering a streamlined workflow. Mobius3D makes patient plan QA faster and easier while supplying details not available from basic meaningful use verification software.

The FDA clearance includes MobiusFX, an optional add-on that utilizes the same independently developed collapsed-cone algorithm with delivery log files to determine 3-D dose delivered to the patient. MobiusFX provides clinicians a new and better way to perform patient-specific QA. Current methods that rely on ion chamber or diode arrays, EPIDs, or film are excessively time consuming, taking anywhere from 30 to 90 minutes per patient to complete and analyze. The long time required often necessitates the need for clinicians to work after hours or weekends in order to accomplish this important QA task. MobiusFX only requires enough time to deliver the beams. This allows QA to be easily achieved during breaks between patients or over a lunch hour, offering an opportunity to reclaim those nights and weekends.

As a true 3-D solution for patient plan and delivery QA, Mobius3D and MobiusFX can provide information that is not available from traditional methods. Customizable DVH objectives, that include RTOG protocols and Task Group 101 recommendations by default, can be used by Mobius3D to tell clinicians if their treatments are meeting goals. MobiusFX compares data from the machine delivery to expected positions from the TPS plan. This provides users confidence that all parameters were delivered exactly as prescribed. Moreover, MobiusFX will extend the IMRT QA process from a pre-treatment check into per-fraction verifications. Lastly, Mobius3D’s intuitive browser-based interface can be accessed with any computer, tablet, or smartphone, making it extremely easy to evaluate results.

For more information: www.mobiusmed.com

Related Content

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin
Sponsored Content | Case Study | Radiation Therapy | May 29, 2019
The so-called “Grey Tsunami” of baby boomers using healthcare services isn’t taking the Radiation Medicine Program at